{"id":7283,"date":"2025-01-29T16:25:00","date_gmt":"2025-01-29T16:25:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-tah-receives-humanitarian-use-device-designation-by-the-u-s-food-and-drug-administration-fda\/"},"modified":"2025-01-29T16:25:00","modified_gmt":"2025-01-29T16:25:00","slug":"realheart-tah-receives-humanitarian-use-device-designation-by-the-u-s-food-and-drug-administration-fda","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-tah-receives-humanitarian-use-device-designation-by-the-u-s-food-and-drug-administration-fda\/","title":{"rendered":"Realheart\u00ae TAH Receives Humanitarian Use Device Designation by the U.S. Food and Drug Administration (FDA)"},"content":{"rendered":"
\n

V\u00e4ster\u00e5s, Sweden, January 29, 2025 \u2013 Scandinavian Real Heart AB (publ) today announces that its total artificial heart, Realheart\u00ae TAH, has been granted Humanitarian Use Device (HUD) designation by the U.S. Food and Drug Administration (FDA). The HUD designation makes Realheart\u00ae TAH eligible to apply for Humanitarian Device Exemption (HDE), an expedited regulatory pathway that can grant the product limited marketing rights.<\/strong><\/p>\n<\/div>\n

\n

Realheart\u00ae TAH is a total artificial heart that mimics the structure and physiological function of the human heart. Following multiple rounds of communication with the FDA, the device has been granted Humanitarian Use Device status which paves the way for Realheart\u00ae TAH to treat patients with advanced biventricular heart failure who have few other options and need to be supported by a total artificial heart.<\/p>\n

HDE is approved if the sponsor can demonstrate data indicating probable safety and benefit to the intended patient group.<\/p>\n

Realheart will continue communications with the FDA to develop a clinical investigation strategy to support a Humanitarian Device Exemption premarket approval.<\/p>\n

\u201cWe are extremely pleased that Realheart\u00ae TAH has been granted Humanitarian Use Device designation by the FDA. It is gratifying to look forward to our efforts culminating in such humanitarian benefit. We look forward to updating the market on further clinical and regulatory activities and meanwhile continue our preclinical development which will be important for a potential future full market approval,\u201d says Ina Laura Perkins, CEO of Realheart.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart\u00ae TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se<\/a><\/p>\n<\/div>\n

\n

This information is information that Scandinavian Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-29 17:25 CET.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong>
Realheart\u00ae TAH Receives Humanitarian Use Device Designation by the U.S. Food and Drug Administration (FDA)<\/a><\/p>\n<\/div>\n